EFG Asset Management Americas Corp. Increases Stake in Danaher Corporation $DHR

EFG Asset Management Americas Corp. lifted its position in Danaher Corporation (NYSE:DHR) by 6.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,255 shares of the conglomerate’s stock after acquiring an additional 2,175 shares during the quarter. Danaher accounts for approximately 1.4% of EFG Asset Management Americas Corp.’s investment portfolio, making the stock its 17th largest holding. EFG Asset Management Americas Corp.’s holdings in Danaher were worth $7,557,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. MGO One Seven LLC boosted its position in Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock valued at $5,145,000 after purchasing an additional 20,813 shares in the last quarter. Chicago Capital LLC lifted its position in shares of Danaher by 11.6% during the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after buying an additional 1,391 shares during the last quarter. UniSuper Management Pty Ltd boosted its holdings in shares of Danaher by 1.6% in the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after buying an additional 2,667 shares in the last quarter. Nvwm LLC grew its position in shares of Danaher by 20.4% in the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after buying an additional 1,204 shares during the last quarter. Finally, ASR Vermogensbeheer N.V. raised its stake in shares of Danaher by 1.9% during the 2nd quarter. ASR Vermogensbeheer N.V. now owns 322,924 shares of the conglomerate’s stock worth $63,787,000 after acquiring an additional 6,136 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Down 1.3%

Danaher stock opened at $222.58 on Thursday. The business’s 50-day simple moving average is $207.29 and its two-hundred day simple moving average is $201.61. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The company has a market cap of $157.22 billion, a PE ratio of 45.89, a PEG ratio of 3.28 and a beta of 0.81. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the business earned $1.71 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a $0.32 dividend. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on DHR shares. Wall Street Zen cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Monday, November 10th. Evercore ISI increased their price objective on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. JPMorgan Chase & Co. raised their price objective on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 target price (down from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Finally, Robert W. Baird set a $247.00 price target on Danaher in a report on Wednesday, October 22nd. Eighteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $243.39.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of the company’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This represents a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,026 shares of company stock valued at $7,195,987 in the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.